Abstract
In this review, we summarize the possible mechanisms of COVID-19-associated coagulopathy and compare its features to other similar conditions. The recent COVID-19 pandemic has caused enormous mortality and morbidity worldwide. It is important to note that COVID-19-associated thrombotic events play a huge role in the morbidity of this disease. Interestingly, it has been observed that this complication may occur despite prophylactic anticoagulant therapy. Recent studies on COVID-19-associated coagulopathy revealed that the COVID-19-associated hypercoagulability is more frequently observed among those with a severe course of the disease. Various mechanisms have been suggested as explanations for this condition and possible underlying etiologies.
MeSH terms
-
Angiotensin-Converting Enzyme 2 / metabolism
-
Anticoagulants / administration & dosage
-
Anticoagulants / adverse effects
-
Blood Coagulation Disorders / etiology*
-
Blood Coagulation Disorders / metabolism
-
COVID-19 / blood
-
COVID-19 / complications*
-
Endothelium, Vascular / metabolism
-
Fibrin Fibrinogen Degradation Products / metabolism
-
Hemostasis
-
Heparin / adverse effects
-
Humans
-
Interleukin-10 / blood
-
Interleukin-6 / blood
-
Receptors, Interleukin-2 / blood
-
SARS-CoV-2* / pathogenicity
-
Thrombophilia / etiology
-
Thrombosis / etiology
-
Tumor Necrosis Factor-alpha / blood
-
Virus Internalization
Substances
-
Anticoagulants
-
Fibrin Fibrinogen Degradation Products
-
Interleukin-6
-
Receptors, Interleukin-2
-
Tumor Necrosis Factor-alpha
-
fibrin fragment D
-
Interleukin-10
-
Heparin
-
Angiotensin-Converting Enzyme 2